Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Bipolar Disorder Therapeutics Market Growth in 2025?

The market for therapeutics for bipolar disorder has witnessed robust growth in recent years. The size of the market is projected to increase from $7.44 billion in 2024 to $7.89 billion in 2025, signifying a compound annual growth rate (CAGR) of 6.0%. The growth witnessed in the historic period can be ascribed to advancements in medical research and development, augmented healthcare spending, an upsurge in the prevalence of mental health disorders, and increased patient advocacy.

What Is the Forecast for the Bipolar Disorder Therapeutics Market Size Through 2029?

In the upcoming years, the market size for therapeutics for bipolar disorder is predicted to experience significant expansion. It is projected to escalate to a value of $9.98 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.1%. The growth projected for this period can be ascribed to several factors such as the rising prevalence of bipolar disorder, governmental initiatives, enhancements in healthcare infrastructure, and an increasing preference for a sedentary lifestyle. The future trends in this period consist of personalized therapy methods, integration of digital health, the development of innovative medicinal products, preventive measures, and the utilisation of neuroimaging and biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6736&type=smp

What are the Key Market Players in Bipolar Disorder Therapeutics Market and How They’re Evolving?

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd, H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

What Are the Primary Growth Drivers in the Bipolar Disorder Therapeutics Market?

The trajectory of the bipolar disorder therapeutics market is being positively influenced by the escalating healthcare expenditure. The term healthcare infrastructure encompasses all financial allocations towards medical care, public health programs, preventive measures, rehabilitation therapies, community health endeavors, and health research. The amplifying healthcare expenditure owes its existence to various considerations such as burgeoning chronic disease occurrences, an aging populace, and escalated medication costs. These elements play a key role in the escalating requirement for healthcare services and treatments. As the collective consciousness about mental health issues expands, so does the diagnosis rate of bipolar disorder which subsequently amplifies the need for therapeutic undertakings. For example, per records from the Canadian Institute for Health Information, a Canada-based non-profit entity, the total health expenditure in Canada is slated to see a 2.8% incline in 2023 following a marginal growth of merely 1.5% in 2022. Consequently, the upward surge in healthcare expenditure is catalyzing the expansion of the bipolar disorder therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6736&type=smp

What Are the Leading Segments in the Global Bipolar Disorder Therapeutics Industry?

The bipolar disorder therapeutics market covered in this report is segmented –

1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs

2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Mood Stabilizers: Lithium, Anticonvulsants, Calcium Channel Blockers

2) By Antipsychotic Drugs: Atypical Antipsychotics, Typical Antipsychotics

3) By Antidepressant Drugs: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs)

4) By Other Drugs: Benzodiazepines, Adjunctive Therapies, Herbal Supplements

What Are the Key Market Trends in the Bipolar Disorder Therapeutics Industry?

The propensity for strategic collaborations is a significant trend that’s increasingly seen in the bipolar disorder therapeutics market. Top companies involved in bipolar disorder therapeutics are concentrating their efforts on forming alliances to strengthen their footholds. In April of 2022, US-based biopharmaceutical firm, BioXcel Therapeutics, Inc., gave the green light to IGALMITM (dexmedetomidine), an FDA-approved sublingual film meant specifically for the immediate relief of agitation in adults suffering from schizophrenia or bipolar I or II disorder. This medication, which rapidly dissolves in one’s mouth, is specifically formulated to alleviate mild, moderate, or severe agitation in these specific patient demographics. Its rapid-acting nature walks hand-in-hand with an immediate management of agitation episodes.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

What Is the Regional Outlook for the Bipolar Disorder Therapeutics Market?

North America was the largest region in the bipolar disorder therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6736

This Report Delivers Insight On:

1. How big is the bipolar disorder therapeutics market, and how is it changing globally?

2. Who are the major companies in the bipolar disorder therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the bipolar disorder therapeutics market right now?

4. Which products or customer segments are growing the most in the bipolar disorder therapeutics market?

5. What factors are helping or slowing down the growth of the bipolar disorder therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model